Highest-materiality recent filing
Cingulate Q1 net loss widens to $9.3M; cash at $25.9M; CTx-1301 PDUFA May 31
Net loss of $9.3M for Q1 2026, up from $3.9M a year ago; G&A expenses surged to $5.7M on commercial build-out.
Cingulate enters $100M at-the-market equity facility with A.G.P.
Entered ATM Sales Agreement with A.G.P./Alliance Global Partners for up to $100M gross proceeds.
Cingulate reports $22.4M FY2025 net loss, CTx-1301 patent allowed, PDUFA May 2026
Net loss of $22.4M for 2025 vs $16.6M in 2024; Q4 net loss $6.3M.
Cingulate closes $12M PIPE financing, appoints Jeff Hargroves to board and converts debt
Cingulate completed $12M private placement led by Falcon Creek Capital at $5.04 per share with 80% warrant coverage
Cingulate closes $6.5M private placement tranche; issues shares for debt
Completed portion of private placement for gross proceeds of $6.5M on Feb 6, 2026; remaining $5.5M expected to close soon.
Cingulate raises ~$12M in private placement of common stock, preferred, and warrants
Gross proceeds ~$12M; issues 2.15M common shares, 973 shares Series A preferred at $1,000 stated value, and warrants for 1.87M shares.
Cingulate issues 426,853 shares to lenders through debt conversion from Nov 21 to Jan 2
Issued shares in six tranches between Nov 21, 2025 and Jan 2, 2026 to settle debt.
CEO Shane Schaffer reinstated after no-contest plea; amended employment agreement modified severance
Shane Schaffer reinstated as CEO Dec 15, 2025, after administrative leave; pled no contest to misdemeanor, received 12 months probation.
Cingulate Q3 net loss $7.3M widens 78% YoY; NDA for CTx-1301 accepted with PDUFA May 31, 2026
Net loss $7.3M vs $4.1M in Q3 2024; operating loss $6.0M on R&D $2.8M (+99.5% YoY) and G&A $3.1M (+69.7%).
Cingulate completes $6M debt financing, appoints Bryan Downey as CCO
Issued $6.57M unsecured promissory note at 9% interest, maturing 18 months, to Avondale Capital for $6M net proceeds.
FDA accepts Cingulate's NDA for CTx-1301 in ADHD; PDUFA date May 31, 2026
FDA accepted NDA for CTx-1301 (dexmethylphenidate), a once-daily PTR stimulant for ADHD in children and adults, under 505(b)(2) pathway.
Cingulate shareholders approve issuance of >20% stock to Lincoln Park Capital
Approved issuance of >20% of common stock to Lincoln Park Capital Fund, LLC under purchase agreement.
John A. Roberts appointed Executive Chairman effective Aug 14; receives $10,000/month cash retainer.
Cingulate Q2 net loss widens to $4.8M; files NDA for CTx-1301 with FDA
Net loss of $4.8M in Q2 2025, up from $3.2M in Q2 2024; R&D spend +43.6% to $2.7M.
CEO Shane Schaffer charged with one count of aggravated domestic battery on August 9, 2025.
Cingulate terminates EVP/COO Laurie A. Myers on August 7, 2025
Laurie A. Myers, Executive Vice President and Chief Operating Officer, terminated.
Cingulate submits NDA to FDA for lead ADHD drug CTx-1301
Submitted NDA on July 31, 2025 for CTx-1301 (dexmethylphenidate) for ADHD.
Cingulate enters $25M equity purchase agreement with Lincoln Park Capital
Lincoln Park Capital commits to buy up to $25M of Cingulate common stock over 36 months, starting after SEC registration effective.
Stockholders authorized a reverse stock split at a ratio between 1:2 and 1:25, to be determined by board before June 10, 2026.
Jeff Ervin and Jay Roberts, will not seek re-election when their respective terms expire at the Company’s 2026 Annual Meeting of Stockholders
Jeff Hargroves has agreed to resign from the Board as a Class I director solely for the purpose of being re-appointed to the Board as a Class II director.
Jeff Ervin and Jay Roberts, will not seek re-election when their respective terms expire at the Company’s 2026 Annual Meeting of Stockholders
Max materiality 0.90 · Median 0.68 · Most common event other_material